Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27777980 | 0.84 | LMNA (0.39) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL135819 | 0.82 | LMNA (0.42) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL2477156 | 0.82 | LMNA (0.42) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL16950494 | 0.82 | LMNA (0.38) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29390294 | 0.81 | TRPA1 (0.56) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL5335913 | 0.81 | TRPA1 (0.56) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL12353580 | 0.79 | PDE3B (0.36) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL30624988 | 0.79 | PDE3B (0.36) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL25474598 | 0.79 | LMNA (0.35) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL12263566 | 0.78 | GABRA1 (0.50) | CYP2A6GABRA1GABRB1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2022087011-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2018-05-24 | — | — | US | disclosed |
| US-20170326142-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | Afferent Pharmaceuticals. Inc. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9724346-B2 | Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | AFFERENT PHARMACEUTICALS INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | AFFERENT PHARMACEUTICALS INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-8846705-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-8524725-B2 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-1725540-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC. | 2012-05-17 | — | — | US | disclosed |
| US-20110160188-A1 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326142-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | P2RX3, P2RX2, P2RX1 | LMNA 4593/4885TRPA1 35/4885CHRM1 126/4885 |
| US-20110160188-A1 | PARAMYXOVIRUS FAMILY INHIBITORS AND METHODS OF USE THEREOF | MAVS, SARS1, CDV3 | LMNA 1391/4885TRPA1 4587/4885CHRM1 4760/4885 |
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3419/4885TRPA1 183/4885CHRM1 459/4885 |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | P2RX3, P2RX2, P2RX5 | LMNA 626/4885TRPA1 234/4885CHRM1 439/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | LMNA 3948/4885TRPA1 3903/4885CHRM1 3556/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | LMNA 3233/4885TRPA1 3126/4885CHRM1 3106/4885 |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3166/4885TRPA1 205/4885CHRM1 500/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | LMNA 2823/4885TRPA1 4813/4885CHRM1 4864/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | LMNA 3453/4885TRPA1 2742/4885CHRM1 4873/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | LMNA 988/4885TRPA1 3709/4885CHRM1 3829/4885 |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX6 | LMNA 4095/4885TRPA1 268/4885CHRM1 185/4885 |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3419/4885TRPA1 183/4885CHRM1 459/4885 |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | LMNA 4079/4885TRPA1 234/4885CHRM1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.